Who is sponsoring NCT02012933?

NCT02012933 is sponsored by Oregon Health and Science University.

What drugs are being tested in NCT02012933?

Interventions in NCT02012933: 3,4-diaminopyridine.

What condition does NCT02012933 study?

NCT02012933 studies Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM).

Is NCT02012933 still recruiting?

NCT02012933 is currently no longer available. Last updated 11 December 2019.

Last reviewed 2019-12-11 · How we verify

NCT02012933

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

NO LONGER AVAILABLE Last updated 11 December 2019

What this trial tests

trial testing 3,4-diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS). No longer available.

Quick facts

Lead sponsor	Oregon Health and Science University
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	1 location across United States

Drugs / interventions tested

3,4-diaminopyridine — full drug profile →

Conditions studied

Lambert-Eaton Myasthenic Syndrome (LEMS) — all drugs for Lambert-Eaton Myasthenic Syndrome (LEMS) →
Congenital Myasthenia (CM) — all drugs for Congenital Myasthenia (CM) →

Sponsor

Oregon Health and Science University

Who can join

2 and older, any sex, with Lambert-Eaton Myasthenic Syndrome (LEMS) or Congenital Myasthenia (CM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle junction. The major symptoms of LEMS are progressive muscle weakness. Many patients experience other symptoms like dry mouth or impotence. Congenital Myasthenia (CM) is an inherited disorder with similar affects and symptoms. 3,4-Diaminopyridine (DAP) is an experimental drug that has improved strength in some subjects with (LEMS). There are no other accepted treatments for LEMS and DAP has relatively few side effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of 3,4-diaminopyridine

Trials testing the same drug.

NCT01765140 — Treatment Use of 3,4-Diaminopyridine · no longer available

Other Oregon Health and Science University trials

Trials by the same sponsor.

NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02012933 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
Last refreshed: 11 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02012933.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing